Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring.

Aging - 19 Jul 2024

Yang Jing, Lin Na, Niu Miaomiao, Yin Boshu

Abstract excerpt

In recent years, the detection and analysis of circulating tumor DNA (ctDNA) have emerged as a new focus in the field of cancer research, particularly in the early diagnosis of hepatocellular carcinoma (HCC) and monitoring of therapeutic efficacy. ctDNA, which refers to cell-free DNA fragments released into the bloodstream from tumor cells upon cell death or shedding, carries tumor-specific genetic and epigenetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to DNA Mutational Analysis

Share to Early Detection of Cancer

Share to Liquid Biopsy

Share to Liver Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 39033781
DOI: 10.18632/aging.205980
PMCID: PMC11315387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring.PMID 39033781Read ↗

Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.Semantic proximity Read ↗

Circulating tumor DNA and its role in detection, prognosis and therapeutics of hepatocellular carcinomaSemantic proximity Read ↗

Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular CarcinomaSemantic proximity Read ↗

Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection TechniquesSemantic proximity Read ↗

The feasibility of using mutation detection in ctDNA to assess tumor dynamics.Semantic proximity Read ↗

Circulating Tumor DNA and Hepatocellular CarcinomaSemantic proximity Read ↗

Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNASemantic proximity Read ↗

Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.Semantic proximity Read ↗

Circulating Tumor DNA as Biomarkers for Cancer DetectionSemantic proximity Read ↗

Revolution of Circulating Tumor DNA: From Bench Innovations to Bedside ImplementationsSemantic proximity Read ↗

Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients’ Management and Therapy OutcomesSemantic proximity Read ↗

Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.